MEDIFIRST SOLUTIONS ANNOUNCES SHAREHOLDER UPDATE
March 22 2016 - 11:05AM
InvestorsHub NewsWire
Freehold, NJ – March 22, 2016 – InvestorsHub NewsWire
-- MEDIFIRST SOLUTIONS, INC. (OTCQB:
MFST) (the “company” or “Medifirst”) would like to update
shareholders on the progress of its FDA 510(k) submission for The
Time Machine Laser Series.
Medifirst is pleased to announce that it has successfully completed
a Skin Surface Temperature Study as requested by the FDA as part of
their most recent request for more information. Using live human
subjects, the test was required to show that the Time Machine Laser
can maintain skin temperature within a specified range of degrees
for a specific treatment times and other details as related to the
usage on the live subjects. The test was performed by Laser Lab
Corp under its approved IRB (Institutional Review Board) status to
perform clinical studies for new possible usages, protocols and
treatments for the Time Machine Laser Series.
Commented CEO Bruce J. Schoengood, “We are very pleased with the
positive results of the Skin Surface Temperature Study and we are
excited to complete the one remaining lab test currently being
performed by Intertek Labs. We are working very diligently
with Intertek and have successfully completed many of the tests as
required as part of the EC 60601-1-2 Medical Electrical Equipment
Part 1-2: General Requirements for Safety: Electromagnetic
Compatibility test as requested by the FDA. Once all the test
results are completed, we will submit all the data to Medifirst’s
FDA consultants to prepare and submit the company response.”
Continued Schoengood, “ Although the deadline to respond back to he
FDA is June, we are still on schedule to complete our response well
in advance of the deadline, and we will continue to update our
progress and completion of our response to be submitted back to the
FDA.”
As recently announced, Laser Lab Corp granted Medifirst Solutions
options to license other fields-of-use for the The Time Machine
Laser Series line as well as other wavelengths and colors.
Furthermore, Laser Lab Corp granted the Company a right of first
refusal allowing Medifirst to review and to consider to license
other technologies. Laser Lab Corp is working on expanding
its multi-site IRB Study nationwide to further its new laser
application claims with hospitals and other medical organizations
with its laser technology lines.
Contact: Investor Relations
Phone: (732) 786-8044
Email:
info@medifirstsolutions.com
Website: www.medifirstsolutions.com
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc. is a Nevada corporation that is
headquartered in New Jersey. The company seeks innovative medical
and healthcare products and technologies which are targeted to both
medical and healthcare professionals, as well as everyday
consumers. Medifirst is developing and establishing both consumer
and professional medical cliental that can serve as a pipeline that
will allow for distribution of future products and services. For
more details visit www.medifirstsolutions.com for more
information.
About the Lasers
Medical Lasers Manufacturer, Inc., a Nevada company, (“MLM”), a
Medifirst subsidiary, will specialize in producing high quality
diode-pumped solid-state lasers. The laser division, including
products and treatment programs, will be operated out of MLM. The
company’s focus is to help patients with specific cosmetic skin
conditions, as well as relief of muscle and joint pain and muscle
spasm and inflammation. Driven by the huge demand for minimally
invasive skin and pain treatments, the global market for medical
and therapeutic lasers have been estimated to grow as high as to $4
billion in 2015.
Forward-Looking Statements: The statements in this press
release that relate to the company's expectations with regard to
the future impact on the company's results from new products in
development are forward-looking statements, and may involve risks
and uncertainties, some of which are beyond our control. Such
risks and uncertainties are described in greater detail in our
filings with the U.S. Securities and Exchange Commission.
Since the information in this press release may contain statements
that involve risk and uncertainties and are subject to change at
any time, the company's actual results may differ materially from
expected results. We make no commitment to disclose any
subsequent revisions to forward-looking statements.